Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors

被引：0
|
作者：
Kelley, Robin Kate
Van Cutsem, Eric
Lee, Michael S.
Wolf, Ido
Fakih, Marwan
de Vos-Geelen, Judith
Lee, Valerie
Vogel, Arndt
Wu, Xi Lawrence
Jin, Fan
Naik, Girish S.
O'Reilly, Eileen Mary
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Leuven KUL, Leuven, Belgium
[3] Univ Hosp Gasthuisberg, Leuven, Belgium
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[6] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[7] Maastricht Univ Med Ctr, Maastricht, Netherlands
[8] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[9] Med Hsch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany
[10] Merck & Co Inc, Kenilworth, NJ USA
[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS669
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] An open-label phase 1 trial of lenvatinib plus pembrolizumab in patients with advanced selected solid tumors
    Kitano, Shigehisa
    Fujiwara, Yutaka
    Shimizu, Toshio
    Iwasa, Satoru
    Yonemori, Kan
    Kondo, Shunsuke
    Shimomura, Akihiko
    Koyama, Takafumi
    Ebata, Takahiro
    Iizumi, Sakura
    Ikezawa, Hiroki
    Namiki, Masayuki
    Kubota, Tomoki
    Miura, Takuma
    Yamamoto, Noboru
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706)
    Kawazoe, Akihito
    Fukuoka, Shota
    Nakamura, Yoshiaki
    Kuboki, Yasutoshi
    Mikamoto, Yuichi
    Shima, Hikari
    Fujishiro, Noriko
    Higuchi, Tsukiko
    Wakabayashi, Masashi
    Nomura, Shogo
    Sato, Akihiro
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
    Balmana, Judith
    Tung, Nadine M.
    Isakoff, Steven J.
    Grana, Begona
    Ryan, Paula D.
    Rafi, Rezvan
    Tracy, Michael
    Winer, Eric
    Baselga, Jose
    Garber, Judy Ellen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
    Kitano, Shigehisa
    Fujiwara, Yutaka
    Shimizu, Toshio
    Iwasa, Satoru
    Yonemori, Kan
    Kondo, Shunsuke
    Shimomura, Akihiko
    Koyama, Takafumi
    Ebata, Takahiro
    Ikezawa, Hiroki
    Hayata, Nozomi
    Minoshima, Yukinori
    Miura, Takuma
    Kubota, Tomoki
    Yamamoto, Noboru
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 90 (06) : 523 - 529
  • [6] A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors
    Shigehisa Kitano
    Yutaka Fujiwara
    Toshio Shimizu
    Satoru Iwasa
    Kan Yonemori
    Shunsuke Kondo
    Akihiko Shimomura
    Takafumi Koyama
    Takahiro Ebata
    Hiroki Ikezawa
    Nozomi Hayata
    Yukinori Minoshima
    Takuma Miura
    Tomoki Kubota
    Noboru Yamamoto
    [J]. Cancer Chemotherapy and Pharmacology, 2022, 90 : 523 - 529
  • [7] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [8] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Brose, Marcia S.
    Cohn, Allen L.
    Mier, James
    Di Simone, Christopher
    Hyman, David M.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Schmidt, Emmett V.
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Aghajanian, Carol
    Taylor, Matthew
    [J]. LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
  • [10] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345